Agenus Inc. (NASDAQ:AGEN) announced that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Under the terms of the agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the 4-Antibody Retrocyte Display® platform. Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration. Agenus Inc (NASDAQ:AGEN) shares after opening at $2.76 moved to $3.06 on last trade day and at the end of the day closed at $3.06. Company price to sales ratio in past twelve months was calculated as 63.43 and price to cash ratio as 6.95. Agenus Inc (NASDAQ:AGEN) showed a positive weekly performance of 19.07%.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) fell -8.51%, the company recently announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to Sativex(R) for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy. Sativex is currently in Phase 3 clinical trials for this indication.GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) shares advanced 5.02% in last trading session and ended the day on $65.24. GWPH return on equity ratio is recorded as -32.70% and its return on assets is -17.90%.
RadNet, Inc. (NASDAQ:RDNT) a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 250 owned and/or operated outpatient imaging centers, announced the completion of the previously announced redemption of all of Radnet Management’s remaining outstanding 10 3/8% Senior Notes due 2018 (the “Notes”). As previously announced, the Company completed a tender offer on April 3, 2014, pursuant to which it had already acquired $193,464,000 aggregate principal amount, or approximately 96.73%, of the original $200 million aggregate principal amount of the Notes. RadNet Inc.(NASDAQ:RDNT) shares moved up 6.08% in last trading session and was closed at $5.06, while trading in range of $ 4.76 – 5.15 . RadNet Inc. (NASDAQ:RDNT) year to date (YTD) performance is 202.90%.
Equities researchers at Brean Capital initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a research report issued on Friday, AnalystRatings.Net reports. The firm set a “buy” rating and a $13.00 price target on the stock. Brean Capital’s target price points to a potential upside of 108.33% from the company’s current price. TG Therapeutics, Inc.(NASDAQ:TGTX) weekly performance is -6.53%. On last trading day company shares ended up $5.15. TG Therapeutics, Inc.(NASDAQ:TGTX) distance from 50-day simple moving average (SMA50) is -18.76%. Analysts mean target price for the company is $12.75.